[A17-65] Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 03.04.2018
Project no.:
A17-65
Commission:
Commission awarded on 21.12.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Diabetes mellitus type 2
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-53 | Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-37 | Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-11 | Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-113 | Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-167 | Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-109 | Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.